Sandbox:Sahar: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Age of onset}} | ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Age of onset}} | ||
!Gender preponderance | !Gender preponderance | ||
!Location | |||
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Clinical features}} | ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Clinical features}} | ||
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Diagnostic feature(s)}} | ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Diagnostic feature(s)}} | ||
Line 13: | Line 14: | ||
| | | | ||
* Male > female | * Male > female | ||
| | |||
* More commonly seen in forearm | |||
* May also affect trunk and upper arm | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Subcutaneous nodule | |||
* Tender to palpation | |||
* Less than 2 cm | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Encapsulated, yellow nodules with a reddish tinge | |||
* A combination of fatty tissue and vascular channels | |||
* Fibrin thrombi is present in vascular channels | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Benign | |||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC; " align="left" | | ! style="padding: 5px 5px; background: #DCDCDC; " align="left" |Myolipoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Fifth and sixth decades of life | |||
* | * | ||
| | | | ||
* Female > male | |||
| | |||
* More commonly seen in retroperitoneum, abdomen, pelvis, inguinal region, or abdominal wall | |||
* May also affect extremities | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Subcutaneous mass which may also engage superficial muscular fascia | |||
* Size differs depending on the location | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Partially encapsulated mass with partially yellow-white cut surface | |||
* A combination of mature adipocytes and sheets of well-differentiated smooth muscle | |||
* No nuclear atypia | |||
* | * | ||
* | * | ||
Line 33: | Line 56: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* | * | ||
| | |||
| | | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 45: | Line 69: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* | * | ||
| | |||
| | | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 57: | Line 82: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* | * | ||
| | |||
| | | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 68: | Line 94: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* | * | ||
| | |||
| | | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | |
Revision as of 20:05, 13 November 2019
Lipomatous tumor | Age of onset | Gender preponderance | Location | Clinical features | Diagnostic feature(s) | Other features |
---|---|---|---|---|---|---|
Angiolipoma |
|
|
|
|
|
|
Myolipoma |
|
|
|
|
|
|
|
|
|
| |||
|
|
|
| |||
|
|
|
| |||
|
|
|
|
Example #1
The patient presented with S.O.B. one year after hysterectomy for a leiomyomatous uterus.